Regeneron continues reign atop the Covid treatment field with expanded EUA for lower dose subcutaneous version of mAb cocktail
The FDA on Friday authorized a new, lower-dose version of Regeneron’s Covid-19 monoclonal antibody cocktail for those with Covid-19 who are at high-risk of progressing to hospitalization.
The new dose is half the originally authorized dose, but the easier-to-administer subcutaneous version may not be the game-changer that experts once envisioned. Regeneron said in a statement that the combo “should be administered by intravenous (IV) infusion” and subcutaneous injections “are an alternative when IV infusion is not feasible and would lead to a delay in treatment.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.